Renal Denervation

This channel includes news and new technology innovations for renal denervation used to treat hypertension. Renal denervation is a catheter-based therapy. The catheter is into the renal artery and delivers radio-frequency energy to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys. This enables greater filtration of the blood and removal of excess water that causes hypertension

  • May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system, patients with high blood pressure who did not respond to treatment with multiple ...

  • April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours ...

  • Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical trial at the 2019 EuroPCR Annual Meeting, May 20-23 in Paris, France. The data indicate that renal denervation (RDN) with the Medtronic Symplicity renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years.

  • ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an investigational device exemption (IDE) supplement to the U.S. Food and Drug Administration (FDA) for a pivotal study of its Paradise System for the treatment of hypertension. Prof. Ajay Kirtane, M.D., of New York-Presbyterian Hospital/Columbia University has taken the role of co-principal investigator for RADIANCE-HTN.

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN
Feature | Hypertension | By Dave Fornell, Editor

May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...

Home May 16, 2021
Home
News | Renal Denervation

December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...

Home December 09, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

Home April 01, 2020
Home
News | Renal Denervation

May 23, 2019 – Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored clinical ...

Home May 23, 2019
Home
News | Atrial Fibrillation | Dave Fornell, Editor

May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to ...

Home May 15, 2019
Home
News | Hypertension

October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and ...

Home October 04, 2018
Home
News | Renal Denervation

May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and ...

Home May 30, 2018
Home
An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.
Feature | Renal Denervation

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now ...

Home May 30, 2018
Home
News | Renal Denervation

May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON ...

Home May 23, 2018
Home
News | Renal Denervation

April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational ...

Home April 16, 2018
Home
News | Renal Denervation

August 31, 2017 — Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial ...

Home August 31, 2017
Home
News | Renal Denervation

October 11, 2016 — Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral ...

Home October 11, 2016
Home
News | Renal Denervation

August 23, 2016 — Technavio analysts forecast the global renal denervation market to grow at a compound annual growth ...

Home August 23, 2016
Home
Subscribe Now